SCM Lifescience Co. Ltd
SCM Lifescience Co., Ltd. operates as a stem cell therapy company in South Korea. It develops SCM-AGH, a treatment for moderate to severe acute pancreatitis and moderate to severe atopic dermatitis, as well as chronic graft versus host disease; and Iroro Deerscalp, a toothbrush cosmetic for hair loss relief. The company was founded in 2014 and is headquartered in Incheon, South Korea.
SCM Lifescience Co. Ltd (298060) - Net Assets
Latest net assets as of September 2025: ₩30.29 Billion KRW
Based on the latest financial reports, SCM Lifescience Co. Ltd (298060) has net assets worth ₩30.29 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩43.99 Billion) and total liabilities (₩13.70 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩30.29 Billion |
| % of Total Assets | 68.86% |
| Annual Growth Rate | N/A |
| 5-Year Change | -77.52% |
| 10-Year Change | N/A |
| Growth Volatility | 122.23 |
SCM Lifescience Co. Ltd - Net Assets Trend (2017–2024)
This chart illustrates how SCM Lifescience Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SCM Lifescience Co. Ltd (2017–2024)
The table below shows the annual net assets of SCM Lifescience Co. Ltd from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩14.18 Billion | -30.75% |
| 2023-12-31 | ₩20.47 Billion | -16.47% |
| 2022-12-31 | ₩24.51 Billion | -45.06% |
| 2021-12-31 | ₩44.61 Billion | -29.28% |
| 2020-12-31 | ₩63.08 Billion | +274.35% |
| 2019-12-31 | ₩16.85 Billion | +137.78% |
| 2018-12-31 | ₩-44.60 Billion | -414.41% |
| 2017-12-31 | ₩-8.67 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to SCM Lifescience Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 17406840435000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩10.23 Billion | 72.18% |
| Other Components | ₩187.31 Billion | 1321.05% |
| Total Equity | ₩14.18 Billion | 100.00% |
SCM Lifescience Co. Ltd Competitors by Market Cap
The table below lists competitors of SCM Lifescience Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Innelec Multimedia
PA:ALINN
|
$2.75 Million |
|
Triangle Energy (Global) Ltd
AU:TEG
|
$2.75 Million |
|
Suvidhaa Infoserve Limited
NSE:SUVIDHAA
|
$2.75 Million |
|
415380
KQ:415380
|
$2.75 Million |
|
Famous Brands Ltd
JSE:FBR
|
$2.75 Million |
|
Euromax Resources Ltd
PINK:EOXFF
|
$2.75 Million |
|
LITHIA MTRS
BE:LMO
|
$2.75 Million |
|
Saint Jean Carbon Inc
OTCQB:TORVF
|
$2.75 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SCM Lifescience Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 20,473,543,660 to 14,178,820,690, a change of -6,294,722,970 (-30.7%).
- Net loss of 12,377,068,010 reduced equity.
- Other factors increased equity by 6,082,345,040.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-12.38 Billion | -87.29% |
| Other Changes | ₩6.08 Billion | +42.9% |
| Total Change | ₩- | -30.75% |
Book Value vs Market Value Analysis
This analysis compares SCM Lifescience Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.12x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩-962.39 | ₩773.00 | x |
| 2018-12-31 | ₩-4870.87 | ₩773.00 | x |
| 2019-12-31 | ₩1837.04 | ₩773.00 | x |
| 2020-12-31 | ₩5312.12 | ₩773.00 | x |
| 2021-12-31 | ₩2746.40 | ₩773.00 | x |
| 2022-12-31 | ₩1496.63 | ₩773.00 | x |
| 2023-12-31 | ₩1000.63 | ₩773.00 | x |
| 2024-12-31 | ₩692.98 | ₩773.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SCM Lifescience Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -87.29%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1500.61%
- • Asset Turnover: 0.04x
- • Equity Multiplier: 1.63x
- Recent ROE (-87.29%) is below the historical average (-77.02%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | -5882.00% | 0.00x | 0.00x | ₩-876.53 Million |
| 2018 | 0.00% | -139404.46% | 0.00x | 0.00x | ₩-35.63 Billion |
| 2019 | -252.54% | -25254.54% | 0.00x | 2.44x | ₩-44.24 Billion |
| 2020 | -15.27% | -3010.19% | 0.00x | 1.21x | ₩-15.94 Billion |
| 2021 | -50.48% | -5126.47% | 0.01x | 1.21x | ₩-26.98 Billion |
| 2022 | -93.55% | -5790.66% | 0.01x | 1.35x | ₩-25.38 Billion |
| 2023 | -117.04% | -3444.23% | 0.03x | 1.24x | ₩-26.01 Billion |
| 2024 | -87.29% | -1500.61% | 0.04x | 1.63x | ₩-13.79 Billion |
Industry Comparison
This section compares SCM Lifescience Co. Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,689,906,881
- Average return on equity (ROE) among peers: -10.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SCM Lifescience Co. Ltd (298060) | ₩30.29 Billion | 0.00% | 0.45x | $2.75 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |